Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to lacutamab for treating adult patients with relapsed or refractory Sézary Syndrome after at least 2 prior systemic therapies including mogamulizumab. The designation is based on Phase 1 and Phase 2 TELLOMAK study results, which showed encouraging efficacy and favorable safety profile in heavily pretreated patients.
The BTD aims to accelerate development and regulatory review of drugs treating serious conditions. This adds to lacutamab's previous Fast Track designation (2019) and PRIME designation by European Medicines Agency (2020). The company is currently aligning with regulatory agencies regarding a confirmatory Phase 3 trial in Cutaneous T Cell Lymphoma and seeking a partnership.
Innate Pharma has announced the dosing of the first patient in its Phase 1 study of IPH4502, a novel antibody-drug conjugate (ADC) targeting Nectin-4, in patients with advanced solid tumors. The study (NCT06781983) will evaluate the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent.
The trial consists of two parts: Part 1 Dose Escalation and Part 2 Dose Optimization, planning to enroll approximately 105 patients. The study targets tumors known to express Nectin-4, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastro-intestinal cancer.
IPH4502 is designed with a differentiated topoisomerase I inhibitor payload, potentially offering benefits for patients with tumors resistant to MMAE-ADC. The drug targets tumors with both high and low Nectin-4 expression levels, supporting its development beyond urothelial carcinoma.
Innate Pharma (Nasdaq: IPHA) has announced an upcoming investor and analyst event focused on its Antibody-Drug Conjugate (ADC) strategy, specifically highlighting IPH4502, their lead Nectin-4 antibody-drug candidate program. The hybrid event will take place in New York on February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.
The company will present the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment. The event will be accessible both in-person and via webcast, with a replay available on Innate Pharma's website.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has released its share and voting rights data as of December 31, 2024. The company reported 83,830,336 ordinary shares, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 84,585,576, which includes voting rights attached to AGAP 2016 (130 voting rights for AGAP 2016-1 and 111 for AGAP 2016-2). The total number of exercisable voting rights is 84,567,001, calculated excluding treasury shares. No voting rights are attached to AGAP 2017.
Innate Pharma (Nasdaq: IPHA) announced a new growth strategy based on three key pillars: driving innovation with their proprietary ANKET® NK-cell engager Platform, accelerating development of Antibody-Drug Conjugates (ADCs), and advancing late-stage assets through partnerships.
The company is developing IPH6501, an ANKET® therapy currently in Phase 1/2 study for CD20-expressing non-Hodgkin's Lymphoma, and IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 in Phase 1 trials for advanced solid tumors.
For late-stage assets, Innate is seeking partners for lacutamab in advanced T cell lymphomas, while monalizumab, partnered with AstraZeneca, is in Phase 3 PACIFIC-9 trial for non-small cell lung cancer with readouts expected by end of 2026.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco. CEO Jonathan Dickinson will present on Tuesday, January 14, 2025, from 11:15 - 11:55 am PST.
The company's executive team, including Dr Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Arvind Sood (EVP, President of US Operations), will participate in 1x1 meetings during the conference. A live video webcast of the presentation will be available on the company's website under the 'Events' tab in the Investors section.
Innate Pharma presented new data from the TELLOMAK Phase 2 study showing quality-of-life improvements in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab. The study included 163 patients: 56 with Sézary syndrome (SS) and 107 with mycosis fungoides (MF).
Key findings for SS patients showed reduction in itch intensity from Week 5, reaching mild levels by Week 13. Skin-related symptoms improved significantly, with Skindex-29 scores decreasing from 52.7 at baseline to 14.4 by Week 45.
For MF patients, itch intensity improved from Week 5, with deeper improvement from Week 37. Skindex-29 scores showed early reductions, decreasing from 56.3 to 38.8 by Week 29.
Translational analysis revealed lacutamab's effectiveness in depleting KIR3DL2-expressing circulating tumor cells and skin cells, supporting its potential as a treatment option for SS patients.
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have announced a partnership worth up to $7.9 million to support the development of IPH6501 in follicular lymphoma. The agreement includes a $3 million upfront investment from IFLI in Innate shares at €1.56 per share, representing 2.26% of Innate's share capital, with potential additional investments of up to $4.9 million tied to milestone achievements.
The collaboration will expand Innate's ongoing Phase 1/2 trial of IPH6501, an anti-CD20 ANKET®, to include patients with relapsed/refractory follicular lymphoma. The trial is currently investigating the safety, tolerability, and preliminary antineoplastic activity in patients with CD20-expressing Non-Hodgkin Lymphoma.
Innate Pharma (Nasdaq: IPHA) announced the selection of multiple abstracts for presentation at the ASH Annual Meeting 2024. The presentations will feature data on lacutamab from the TELLOMAK Phase 2 trial, including health-related quality of life and translational analysis in patients with Sézary Syndrome. Additionally, data will be presented on SAR443579, a Sanofi-partnered ANKET® asset, in combination with venetoclax and azacitidine for newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its financial calendar for 2025. The schedule includes four major financial disclosures: 2024 financial statements on March 27, first quarter 2025 revenue and cash position on May 13, half-year financial statements on September 17, and third quarter 2025 revenue and cash position on November 13. The company's Annual General Shareholders Meeting is scheduled for May 22, 2025. All financial reports will be released before market open CET.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
